Your browser doesn't support javascript.
loading
The pharmacogenetics of treatment with olanzapine.
Zubiaur, Pablo; Soria-Chacartegui, Paula; Villapalos-García, Gonzalo; Gordillo-Perdomo, Juan J; Abad-Santos, Francisco.
Affiliation
  • Zubiaur P; Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.
  • Soria-Chacartegui P; UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.
  • Villapalos-García G; Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.
  • Gordillo-Perdomo JJ; Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.
  • Abad-Santos F; Department of Clinical Analysis, Hospital Universitario de La Princesa, Madrid, 28006, Spain.
Pharmacogenomics ; 22(14): 939-958, 2021 09.
Article in En | MEDLINE | ID: mdl-34528455
Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and efficacy. The aim of this systematic review is to describe all clinically relevant pharmacogenetic information on olanzapine and to propose clinically actionable variants. Two hundred and eighty-four studies were screened; 76 complied with the inclusion criteria and presented significant associations. DRD2 Taq1A (rs1800497) *A1, LEP -2548 (rs7799039) G and CYP1A2*1F alleles were related to olanzapine effectiveness and safety variability in several studies, with a high level of evidence. DRD2 -141 (rs1799732) Ins, A-241G (rs1799978) G, DRD3 Ser9Gly (rs6280) Gly, HTR2A rs7997012 A, ABCB1 C3435T (rs1045642) T and G2677T/A (rs2032582) T and UGT1A4*3 alleles were related to safety, effectiveness and/or pharmacokinetic variability with moderated level of evidence.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pharmacogenetics / Polymorphism, Genetic / Schizophrenia / Antipsychotic Agents / Olanzapine Type of study: Systematic_reviews Limits: Humans Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2021 Type: Article Affiliation country: Spain
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pharmacogenetics / Polymorphism, Genetic / Schizophrenia / Antipsychotic Agents / Olanzapine Type of study: Systematic_reviews Limits: Humans Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2021 Type: Article Affiliation country: Spain